期刊刊名：健康管理學刊 　 卷期：12卷2期

篇名出版日期：2014年12月1日

作者：范紀鎮,孔建民, Chi-Chen Fan, Chien-Min Kung

語言：English

關鍵字：Colorectal cancer, targeted drug therapy, EGFR, KRAS,結腸直腸癌,標靶藥物治療,KRAS

被點閱次數：2次

閱讀時間：5sec

摘要：
Anti-epidermal growth factor receptor targeted therapy is typically used to treat colorectal cancer (CRC). The KRAS gene status is one of eligible situations for treating CRC patients with targeting drugs. This study was to clarify the recent prevalence of KRAS gene mutation in CRC patients with epidermal growth factor receptor (EGFR) expression in Taiwan. One hundred and sixty-four patients (mean age, 61.80±12.78 years) who suffered from CRC were enrolled in this study at Mackay Memorial Hospital in Taiwan. Among those CRC paraffin-embedded tissues, 48 subjects with EGFR expression were detected by immunohistochemical method, and those Kirsten RAS (KRAS) gene were amplified using the Sanger sequencing method. The KRAS mutations in codons 12 and 13 were found in 50.00% of all EGFR-expressing CRC patients, and in 41.67% of metastatic CRC patients. The most frequent mutations were those on codon 12 (75.00%), especially glycine-to-aspartate (G12D, 50.00%) and glycine-to-valine (G12V, 12.50%) mutations. A 25.00% mutation on codon 13 was mostly glycine-to-aspartate (G13D, 25.00%). This study identified a high frequency of KRAS somatic mutation in CRC with EGFR expressed patients.

　　　　　[全文下載]